hydrochlorothiazide/triamterene; HCTZ/triamterene (Dyazide, Maxzide, Maxide)
Jump to navigation
Jump to search
Introduction
HCTZ/triamterene 50/75, 25/37.5.
Indications
- management of mild to moderate hypertension
- treatment of edema in congestive heart failure & nephrotic syndrome
- treatment of hypokalemia in patients taking HCTZ
* minimally lowers blood pressure relative to HCTZ alone (4 mm Hg systolic BP, 1 mm Hg diastolic BP)[4]
Dosage
Tabs: HCTZ/triamterene 25/37.5, 25/50
Stability: protect from light.
Adverse effects
- not common (1-10%)
- uncommon (< 1%)
- dizziness, electrolyte disturbances, bright orange tongue, burning of tongue, cracked corners of mouth, aplastic anemia, hemolytic anemia, megaloblastic anemia, agranulocytosis, leukopenia, thrombocytopenia, purpura, allergic pneumonitis, pulmonary edema, respiratory distress, xanthopsia, transient blurred vision, muscle cramps, fatigue
* see hydrochlorothiazide & triamterene
Drug interactions
see hydrochlorothiazide & triamterene
Laboratory
Mechanism of action
see hydrochlorothiazide & triamterene
More general terms
Components
References
- ↑ The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- ↑ Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998 Department of Veterans Affairs, VA National Formulary
- ↑ Kaiser Permanente Northern California Regional Drug Formulary, 1998
- ↑ 4.0 4.1 Tu W et al. Triamterene enhances the blood pressure lowering effect of hydrochlorothiazide in patients with hypertension. J Gen Intern Med 2016 Jan; 31:30 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26194642 <Internet> http://link.springer.com/article/10.1007%2Fs11606-015-3469-1